PL366035A1 - Sposób i kompozycja do leczenia raka przez podawanie środków chemioterapeutycznych wywołujących apoptozę - Google Patents
Sposób i kompozycja do leczenia raka przez podawanie środków chemioterapeutycznych wywołujących apoptozęInfo
- Publication number
- PL366035A1 PL366035A1 PL01366035A PL36603501A PL366035A1 PL 366035 A1 PL366035 A1 PL 366035A1 PL 01366035 A PL01366035 A PL 01366035A PL 36603501 A PL36603501 A PL 36603501A PL 366035 A1 PL366035 A1 PL 366035A1
- Authority
- PL
- Poland
- Prior art keywords
- apoptosis
- administration
- composition
- treating cancer
- chemotherapeutic agents
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19592000P | 2000-04-10 | 2000-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL366035A1 true PL366035A1 (pl) | 2005-01-24 |
Family
ID=22723363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL01366035A PL366035A1 (pl) | 2000-04-10 | 2001-04-10 | Sposób i kompozycja do leczenia raka przez podawanie środków chemioterapeutycznych wywołujących apoptozę |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20020041888A1 (pl) |
| EP (1) | EP1274404A1 (pl) |
| JP (1) | JP2004507451A (pl) |
| KR (1) | KR20030008368A (pl) |
| CN (1) | CN1438882A (pl) |
| AU (1) | AU2001253334A1 (pl) |
| BR (1) | BR0110150A (pl) |
| CA (1) | CA2406484A1 (pl) |
| CZ (1) | CZ20023333A3 (pl) |
| EA (1) | EA200201068A1 (pl) |
| HU (1) | HUP0302296A2 (pl) |
| IL (1) | IL152180A0 (pl) |
| MX (1) | MXPA02009984A (pl) |
| NO (1) | NO20024867L (pl) |
| PL (1) | PL366035A1 (pl) |
| SK (1) | SK14452002A3 (pl) |
| WO (1) | WO2001076567A1 (pl) |
| YU (1) | YU77002A (pl) |
| ZA (1) | ZA200208167B (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| CA2482941A1 (en) * | 2002-04-26 | 2003-11-06 | Teva Pharmaceutical Industries Ltd. | Microparticle pharmaceutical compositions for intratumoral delivery |
| CN1319525C (zh) * | 2004-09-16 | 2007-06-06 | 北京圣医耀科技发展有限责任公司 | 紫杉醇-海藻酸钠微球血管栓塞剂及其制备 |
| AU2005299748B2 (en) * | 2004-10-21 | 2009-04-09 | Tgel Bio Co., Ltd | In situ controlled release drug delivery system |
| CN103169729A (zh) | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CA2601067A1 (en) | 2005-05-04 | 2006-11-09 | Medigene Ag | Method of administering a cationic liposomal preparation comprising paclitaxel |
| CA2646156C (en) | 2006-03-22 | 2016-05-24 | Medigene Ag | Treatment of triple receptor negative breast cancer |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| EP3925625A1 (en) * | 2011-01-09 | 2021-12-22 | ANP Technologies, Inc. | Hydrophobic molecule-induced branched polymer aggregates and their use |
| WO2021138646A1 (en) | 2020-01-03 | 2021-07-08 | Privo Technologies, Inc. | Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4345588A (en) * | 1979-04-23 | 1982-08-24 | Northwestern University | Method of delivering a therapeutic agent to a target capillary bed |
| US4492720A (en) * | 1983-11-15 | 1985-01-08 | Benjamin Mosier | Method of preparing microspheres for intravascular delivery |
| HUP9701554D0 (en) * | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
-
2001
- 2001-04-10 CZ CZ20023333A patent/CZ20023333A3/cs unknown
- 2001-04-10 MX MXPA02009984A patent/MXPA02009984A/es unknown
- 2001-04-10 BR BR0110150-1A patent/BR0110150A/pt not_active IP Right Cessation
- 2001-04-10 JP JP2001574085A patent/JP2004507451A/ja active Pending
- 2001-04-10 EA EA200201068A patent/EA200201068A1/ru unknown
- 2001-04-10 AU AU2001253334A patent/AU2001253334A1/en not_active Abandoned
- 2001-04-10 EP EP01926824A patent/EP1274404A1/en not_active Withdrawn
- 2001-04-10 IL IL15218001A patent/IL152180A0/xx unknown
- 2001-04-10 HU HU0302296A patent/HUP0302296A2/hu unknown
- 2001-04-10 WO PCT/US2001/011688 patent/WO2001076567A1/en not_active Ceased
- 2001-04-10 CA CA002406484A patent/CA2406484A1/en not_active Abandoned
- 2001-04-10 US US09/829,621 patent/US20020041888A1/en not_active Abandoned
- 2001-04-10 KR KR1020027013576A patent/KR20030008368A/ko not_active Withdrawn
- 2001-04-10 SK SK1445-2002A patent/SK14452002A3/sk unknown
- 2001-04-10 PL PL01366035A patent/PL366035A1/pl unknown
- 2001-04-10 CN CN01810833A patent/CN1438882A/zh active Pending
-
2002
- 2002-04-10 YU YU77002A patent/YU77002A/sh unknown
- 2002-10-09 NO NO20024867A patent/NO20024867L/no not_active Application Discontinuation
- 2002-10-10 ZA ZA200208167A patent/ZA200208167B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001253334A1 (en) | 2001-10-23 |
| ZA200208167B (en) | 2004-02-10 |
| CN1438882A (zh) | 2003-08-27 |
| KR20030008368A (ko) | 2003-01-25 |
| MXPA02009984A (es) | 2004-09-10 |
| CA2406484A1 (en) | 2001-10-18 |
| US20020041888A1 (en) | 2002-04-11 |
| CZ20023333A3 (cs) | 2003-06-18 |
| WO2001076567A1 (en) | 2001-10-18 |
| NO20024867D0 (no) | 2002-10-09 |
| IL152180A0 (en) | 2003-05-29 |
| NO20024867L (no) | 2002-12-06 |
| JP2004507451A (ja) | 2004-03-11 |
| SK14452002A3 (sk) | 2003-07-01 |
| EA200201068A1 (ru) | 2003-12-25 |
| HUP0302296A2 (hu) | 2003-10-28 |
| BR0110150A (pt) | 2004-04-27 |
| YU77002A (sh) | 2005-09-19 |
| EP1274404A1 (en) | 2003-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6147401A (en) | Compositions and methods for the treatment of cancer | |
| EP1229934A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER BY MEANS OF IMMUNO-CONJUGATES AND CHEMOTHERAPEUTIC AGENTS | |
| AU4768301A (en) | Synergistic methods and compositions for treating cancer | |
| EP1355563A4 (en) | METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES | |
| AU2002364211A1 (en) | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents | |
| HUP0203304A3 (en) | Method and composition for chemoprevention of prostate cancer | |
| IL152180A0 (en) | Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents | |
| PL352931A1 (pl) | Kompozycje i zastosowanie ET 743 w leczeniu raka | |
| AU2002340168A1 (en) | Treatment of prostate cancer by inhibitors of ncam2 | |
| AU5160201A (en) | Compositions comprising natural agents for treatment of cancer | |
| HUP0300848A3 (en) | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | |
| AU2001278558A1 (en) | Use of co for treating inflammation of upper airways or bronchi | |
| EP1463495A4 (en) | AGENTS AND METHODS FOR TREATING CANCER | |
| IL145397A0 (en) | Compositions and methods for treatment of cancer | |
| IL124650A0 (en) | Methods and therapeutic compositions for treating cancer | |
| EP1349485A4 (en) | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA | |
| PL368035A1 (pl) | Kompozycje i sposoby leczenia raka | |
| AU2001253836A1 (en) | Method of treating cancer | |
| HUP0300860A3 (en) | Pharmaceutical compositions suitable for treatment of urinary dysfunction | |
| HUP0302430A3 (en) | Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontience | |
| AU3483001A (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| AU2001278738A1 (en) | Medicinal compositions for preventing and treating cancer | |
| IL154354A0 (en) | Composition for prophylaxis and treatment of cancer | |
| AUPR644301A0 (en) | Method and composition for treatment of cancer | |
| AU2002337713A1 (en) | Pharmaceutical compositions and methods for treating cancer |